



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, email: info@bafnapharma.com, Website, www.bafnapharma.com
CIN : L24294 TN1995PLC030698

Date: 01st September 2020

Listing Department BSE Limited P J Towers Dalal Street, Mumbai – 400 001	Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051
Security code : 532989 Security ID : BAFNAPHARM	Symbol : BAFNAPHSeries : EQ

Dear Sir,

Sub.:- Intimation of Board meeting of the Company to inter-alia consider and approve the un-audited financial results for the quarter ending 30th June 2020

Ref.:- Regulation 29(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday, 10th September 2020 online through video conferencing, to inter alia consider and adopt un-audited financial results for the first quarter ending 30th June 2020 and preferential allotment of 21290701 shares to SRJR Lifesciences LLP pursuant to the Order passed by NCLT, Chennai as part of approved Resolution Plan under IBC 2016 and any other business with the permission of the Chair. The Company has already received In-principle approval from NSE for preferential allotment and awaiting In-principle approval from BSE.

Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in securities of the Company shall remain closed until 48 hours after the financial results approved at the meeting are made public.

Thanking you.

Yours faithfully,
For BAFNA PHARMACEUTICALS LIMITED

Jitendra Kumar Pal
Company Secretary

